Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study data from M. Kurosumi et al provide new insights into breast cancer
July 10th, 2008
According to recent research from Ina, Japan, " The PReOperative 'Arimidex'(R) Compared with Tamoxifen (PROACT) trial compared neoadjuvant anastrozole and tamoxifen in postmenopausal women with large, operable or potentially operable, locally advanced hormone receptor-positive breast cancer. Here, we compare objective clinical responses with histopathological tumor responses to therapy in a cohort of 97 Japanese patients, in order to investigate the consistency of assessment methods and the change in estrogen-receptor (ER) and progesterone-receptor (PgR) status." " Histopathological response and the change in ER and PgR status were assessed by comparing pathological...
Source: Women's Health Weekly (2008-07-10)
|
